In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates

被引:10
作者
Chandramohan, Yuvaraj [1 ]
Padmanaban, Venkatesan [1 ]
Bethunaickan, Ramalingam [1 ,4 ]
Tripathy, Srikanth [2 ]
Swaminathan, Soumya [3 ]
Ranganathan, Uma Devi [1 ]
机构
[1] Natl Inst Res TB, Dept Immunol, 1 Mayor Sathyamoorthy Rd, Chennai 600031, Tamil Nadu, India
[2] Natl Inst Res TB, Chennai 600031, Tamil Nadu, India
[3] Indian Council Med Res, New Delhi 110029, India
[4] ICMR Natl Inst Nutr, Pathol & Microbiol Div, Hyderabad, India
关键词
REMA; Tuberculosis; Synergy; Anti-TB drugs; Bedaquiline; Delamanid; COMBINATION; RESISTANCE; ANTAGONISM; CANDIDATES; THERAPY; SQ109;
D O I
10.1016/j.jgar.2019.06.013
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: The emergence of drug-resistant tuberculosis (TB) poses a serious challenge to existing anti-TB therapies. Hence, there is a direct need for identification of new drugs and effective combination regimens. Methods: In this study, minimum inhibitory concentrations (MICs) of the anti-TB drugs bedaquiline (BDQ), delamanid (DEL) and moxifloxacin (MFX) were evaluated using a resazurin microtiter assay (REMA) against five drug-resistant clinicalMycobacterium tuberculosis (MTB) isolates as well as the drug-susceptible reference strain H37Rv. In addition, their fractional inhibitory concentration indices (FICIs) were evaluated using a REMA-based calorimetric chequerboard assay to assess their interaction profiles against the MTB isolates. Results: The FICI indicated that BDQ acted synergistically with DEL against isoniazid (INH)-monoresistant, rifampicin (RIF)-monoresistant and extensively drug-resistant (XDR) clinical MTB isolates. In addition, the combination of DEL acted synergistically with MFX against INH-monoresistant, RIF-monoresistant and XDR clinical MTB isolates. Moreover, the combination of BDQ and MFX showed a synergistic effect against RIF-monoresistant and pre-XDR clinical MTB isolates. DEL at 0.125 x MIC (i.e. 0.015 mu g/mL) used in combination with BDQ at 0.25 x MIC (i.e. 0.015 mu g/mL) had a stronger bactericidal effect against the XDR-TB clinical isolate than DEL alone at 1 x MIC (i.e. 0.125 mu g/mL). Conclusion: Synergistic and additive effects between these two-drug combinations offer an attractive chemotherapeutic regimen against drug-resistant clinical MTB isolates. (C) 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:348 / 353
页数:6
相关论文
共 33 条
[21]   Synergy, antagonism, and what the chequerboard puts between them [J].
Odds, FC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (01) :1-1
[22]   Resazurin microtiter assay plate:: Simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis [J].
Palomino, JC ;
Martin, A ;
Camacho, M ;
Guerra, H ;
Swings, J ;
Portaels, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2720-2722
[23]   In Vitro Interactions between New Antitubercular Drug Candidates SQ109 and TMC207 [J].
Reddy, Venkata M. ;
Einck, Leo ;
Andries, K. ;
Nacy, Carol A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (07) :2840-2846
[24]  
Sala C, 2011, FUTURE MICROBIOL, V6, P617, DOI [10.2217/fmb.11.46, 10.2217/FMB.11.46]
[25]   Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration [J].
Shi, LB ;
Sohaskey, CD ;
Kana, BD ;
Dawes, S ;
North, RJ ;
Mizrahi, V ;
Gennaro, ML .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (43) :15629-15634
[26]   PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release [J].
Singh, Ramandeep ;
Manjunatha, Ujjini ;
Boshoff, Helena I. M. ;
Ha, Young Hwan ;
Niyomrattanakit, Pornwaratt ;
Ledwidge, Richard ;
Dowd, Cynthia S. ;
Lee, Ill Young ;
Kim, Pilho ;
Zhang, Liang ;
Kang, Sunhee ;
Keller, Thomas H. ;
Jiricek, Jan ;
Barry, Clifton E., III .
SCIENCE, 2008, 322 (5906) :1392-1395
[27]   SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis [J].
Tahlan, Kapil ;
Wilson, Regina ;
Kastrinsky, David B. ;
Arora, Kriti ;
Nair, Vinod ;
Fischer, Elizabeth ;
Barnes, S. Whitney ;
Walker, John R. ;
Alland, David ;
Barry, Clifton E., III ;
Boshoff, Helena I. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (04) :1797-1809
[28]   Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention [J].
Thi Van Anh Nguyen ;
Anthony, Richard M. ;
Banuls, Anne-Laure ;
Thi Van Anh Nguyen ;
Dinh Hoa Vu ;
Alffenaar, Jan-Willem C. .
CLINICAL INFECTIOUS DISEASES, 2018, 66 (10) :1625-1630
[29]   Drug susceptibility testing of Mycobacterium tuberculosis complex by use of a high-throughput, reproducible, absolute concentration method [J].
van Klingeren, Bert ;
Dessens-Kroon, Mirjam ;
van der Laan, Tridia ;
Kremer, Kristin ;
van Soolingen, Dick .
JOURNAL OF CLINICAL MICROBIOLOGY, 2007, 45 (08) :2662-2668
[30]   Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid [J].
Wells, Charles D. ;
Gupta, Rajesh ;
Hittel, Norbert ;
Geiter, Lawrence J. .
EUROPEAN RESPIRATORY JOURNAL, 2015, 45 (05) :1498-1501